Project Details
Description
The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to fingolimod before (up to 8 weeks before last menstrual period (LMP) and during pregnancy in routine clinical practice. The overall aim is to collect and evaluate data on maternal, fetal, and infant outcomes and compare it with reference populations.
| Status | Active |
|---|---|
| Effective start/end date | 15/10/11 → 2/01/31 |
Collaborative partners
- Novartis Pharmaceuticals (lead)
- Dubai Health Authority
- Abu Dhabi Health Services Company
Keywords
- Pathologic Processes
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Nervous System Diseases
- Demyelinating Diseases
- Autoimmune Diseases
- Immune System Diseases
- Multiple Sclerosis
- Sclerosis
- Sphingosine 1 Phosphate Receptor Modulators
- Molecular Mechanisms of Pharmacological Action
- Immunosuppressive Agents
- Immunologic Factors
- Physiological Effects of Drugs
- Fingolimod Hydrochloride
- Fingolimod
- FTY720
- Gilenya
- MS
- Safety
- Pregnancy
- Pregnancy Outcomes
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.